Halozyme Therapeutics HALO Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| —— | —— | $595.49M+6.9% | $557.28M+14.8% | $485.36M+9.3% | ||
| $12.93M+13.5% | $11.39M+6.1% | $10.74M+0.9% | $10.64M+0.9% | $10.54M+2.4% | ||
| $57.53M+11.6% | $51.57M+11.0% | $46.46M-0.9% | $46.87M+6.1% | $44.18M+1.8% | ||
| —— | —— | —— | —— | —— | ||
| —— | $48.7M+33.3% | $36.53M+50.0% | $24.35M+100% | $12.18M— | ||
| $151.44M+18.3% | $128.06M+112% | $60.29M-40.8% | $101.82M-6.3% | $108.72M+46.4% | ||
| -$30.52M-1,095% | -$2.55M-111% | $23.95M+4.8% | $22.85M-23.1% | $29.71M-57.2% | ||
| -$27.93M-550% | $6.21M-72.5% | $22.55M+245% | $6.53M-82.6% | $37.53M-20.1% | ||
| —— | —— | $55.76M+1,934% | -$3.04M-169% | $4.43M+183% | ||
| $88.41M+15.3% | $76.66M+7.9% | $71.05M0.0% | $71.05M0.0% | $71.05M0.0% | ||
| $7.91M+5.3% | $7.51M+1.4% | $7.4M+0.2% | $7.38M+0.2% | $7.37M+0.2% | ||
| $677.42M+4.0% | $651.56M+6.6% | $611M+11.5% | $547.78M+8.7% | $503.86M+5.2% | ||
| $9.76M+40.0% | $6.97M-18.9% | $8.6M+21.4% | $7.08M-12.6% | $8.1M-24.3% | ||
| $116.56M-52.9% | $247.36M-17.2% | $298.8M-50.0% | $597.82M+1.6% | $588.48M-9.1% | ||
| $681.08M-5.7% | $722.25M+35.5% | $532.85M+15.5% | $461.26M+41.4% | $326.11M-17.6% | ||
| —— | $284.89M+33.3% | $213.67M+50.0% | $142.44M+100% | $71.22M— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | -$571.1M-7.7% | -$530.14M-139% | -$221.69M-1.3% | ||
| —— | —— | $265.35M+311% | -$126M-1,177% | $11.7M+564% | ||
| —— | $11.43M+1.9% | $11.21M+2.0% | $11M+2.0% | $10.78M+2.0% | ||
| —— | $134.64M+11.1% | $121.14M+12.5% | $107.63M+14.3% | $94.12M+16.8% | ||
| $1.62M-50.9% | $3.3M-41.1% | $5.6M-33.1% | $8.36M-18.5% | $10.26M-6.0% | ||
| $7.91M+5.3% | $7.51M+1.4% | $7.4M+0.2% | $7.38M+0.2% | $7.37M+0.2% | ||
| $88.41M+15.3% | $76.66M+7.9% | $71.05M0.0% | $71.05M0.0% | $71.05M0.0% | ||
| -$912K+4.1% | -$951K-7.6% | -$884K+17.2% | -$1.07M+2.9% | -$1.1M-3.1% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | $55.76M+1,934% | -$3.04M-169% | $4.43M+183% | ||
| —— | $284.89M+33.3% | $213.67M+50.0% | $142.44M+100% | $71.22M— | ||
| —— | $287.77M+33.3% | $215.83M+50.0% | $143.89M+100% | $71.94M— | ||
| —— | —— | —— | —— | —— | ||
| —— | $722.25M+12.7% | $640.58M+14.6% | $558.91M+17.1% | $477.24M+20.6% | ||
| —— | —— | —— | —— | —— | ||
| —— | $5.48M+33.3% | $4.11M+50.0% | $2.74M+100% | $1.37M— | ||
| —— | —— | —— | $2.34M+21.4% | $1.93M-37.3% | ||
| —— | $134.64M+11.1% | $121.14M+12.5% | $107.63M+14.3% | $94.12M+16.8% | ||
| $667.65M+3.6% | $644.59M+7.0% | $602.4M+11.4% | $540.69M+9.1% | $495.76M+5.8% | ||
| $667.65M+3.6% | $644.59M+7.0% | $602.4M+11.4% | $540.69M+9.1% | $495.76M+5.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Halozyme Therapeutics generate?
- Halozyme Therapeutics (HALO) generated $677.4M in operating cash flow over the trailing twelve months.
- What is Halozyme Therapeutics's free cash flow?
- After $9.8M of capital expenditures, Halozyme Therapeutics's free cash flow was $667.7M over the trailing twelve months, up 34.7% year over year.
- Where does Halozyme Therapeutics's cash flow data come from?
- Every line is extracted from Halozyme Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
